Language
Country/Area
No result found
The Secret Hidden in Empagliflozin: Why is this drug classified as an essential drug by the World Health Organization?
Empagliflozin is an oral antidiabetic drug that provides an important benefit to modern medicine by improving glycemic control in patients with type 2 diabetes. Since its approval in the United States and the European Union in 2014, the use of empagliflozin has gradually expanded and in 2022 became the 56th most commonly prescribed drug in the United States, available to patients aged 10 years and older. Notably, Empagliflozin not only benefits patients with diabetes, but also provides significant health benefits to those with heart disease or chronic kidney disease.
Empagliflozin's primary action is as an inhibitor of the sodium-glucose co-transporter 2 (SGLT-2), which helps lower blood sugar by inhibiting glucose reabsorption by the kidneys.
Many studies have shown that the use of empagliflozin can reduce the death and hospitalization rates in patients with heart disease. Empagliflozin has shown significant preventive effects on cardiovascular events associated with heart failure, making it one of the standard treatments for heart disease patients. This is especially important because heart disease and diabetes often go together, creating a vicious cycle.
Empagliflozin's effect is not only to control blood sugar, but also to stabilize kidney function and reduce the risk of heart attack.
However, the use of empagliflozin is not without risks. Common side effects include shortness of breath, loss of appetite, and abdominal discomfort; less common but potentially fatal side effects include sausage ulcers and ketoacidosis. In addition, because the drug may cause a decrease in renal function in the short term, special caution is required when using it in patients with impaired renal function.
Despite these risks, additional research suggests that empagliflozin use may not increase the risk of adverse kidney events, even in certain patients with poor kidney function, according to the health agency. This makes empagliflozin the first option many doctors consider when facing patients with complex medical histories.
"Empagliflozin is more than just a glucose-lowering drug; it is an important tool for improving overall health" - Medical review experts.
Empagliflozin not only improved glycemic control, but also showed favorable effects on body weight and blood pressure. In multiple clinical trials, patients experienced an average weight loss of about 2% and a slight reduction in blood pressure. This is a significant benefit for people with diabetes and heart disease, as these populations often face multiple challenges in managing their health.
As the number of people using empagliflozin increases, monitoring and evaluation of this drug becomes particularly important. As research continues, more data will emerge about how this drug works and its potential benefits. These conclusions will not only promote advances in clinical practice, but will also improve the overall health of patients.
Another study showed that Empagliflozin is not only beneficial for patients with type 2 diabetes, but also shows unprecedented effects in the treatment of patients with chronic heart disease and kidney disease.
Globally, Empagliflozin is listed as an essential medicine by the World Health Organization, meaning it is of paramount importance for improving public health. Every healthcare provider should recognize the potential of empagliflozin and incorporate it into treatment plans to improve the quality of life of patients.
The thought-provoking question is: In future health management, can we fully understand and safely and effectively use new anti-diabetic drugs, such as Empagliflozin, to save more lives and health?
